TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

R K Kelley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.